Interestingly, co-treatment of an MMP-2/-9 inhibitor and PD-1 or CTLA-4 blockade enhanced the therapeutic efficacy in the treatment of mouse models of melanoma and lung cancer (Ye et al., 2020). This evidence concerns the gene CTLA4 and melanoma.